- Policy
- Pts can participate in Phase III tx for terminal cancer
- by Lee, Tak-Sun Sep 30, 2021 05:57am
- The MFDS announced on the 29th that it has revised and distributed the "Guidelines for applying rapid screening of medicines" so that even early cancer patients can participate in clinical trials, considering the difficulty of recruiting large-scale phase 3 clinical trials for terminal cancer patients. However, even in the early stages of the
- Policy
- 24 new drugs receive ₩177.9 billion benefit this year
- by Kim, Jung-Ju Sep 30, 2021 05:56am
- A total of 24 new drugs were newly listed or expanded reimbursement standards by this month, improving patient accessibility. Among new drugs that were already listed, reimbursement standards for 4 products were extended, improving coverage. Although only 10,000 patients in Korea will benefiting from the extension, the result could be interp
- Policy
- Will a treatment for resistant hypertension be released?
- by Lee, Tak-Sun Sep 29, 2021 05:54am
- Attention is focused on whether a treatment for resistant hypertension that cannot be controlled with existing drugs, that is in the final stages of its clinical trial, will succeed in commercialization. The drug is firibastat, that is developed by Quantum Genomics. Dong Wha Pharmaceuticals owns exclusive commercialization rights to supp
- Policy
- DUR check for more than 28 days of Zolpidem combined Rx
- by Lee, Hye-Kyung Sep 29, 2021 05:54am
- In the future, 49 drug ingredients, such as "Zolpidem," that should be careful during the administration period, will also be checked for drugs that exceed the maximum administration period by adding up the number of prescription days. The HIRA announced that it will apply "improvement of DUR inspection standards" to 345 items (213 reimubrsed dr
- Policy
- Delstrigo listed at ₩19,491 … Zejula’s price cut 6%
- by Kim, Jung-Ju Sep 29, 2021 05:53am
- MSD Korea’s fixed-dose combination product Delstrigo (doravirine·lamivudine·tenofovir disoproxil fumarate) will be listed with insurance benefit next month, at &8361;19,491. Also, reimbursement for Takeda Korea’s Zejula cap. 100mg (niraparib) has been extended to cover monotherapy for ovarian cancer, upon which the price was cut by 6% and w
- Policy
- Domestic venture introduces new imported breast cancer drug
- by Lee, Tak-Sun Sep 28, 2021 05:54am
- As domestic startup is imminent to introduce new breast cancer drug from overseas, Geo-Young is in charge of third-party logistics of the drug, drawing attention. This is because it is different from the existing anticancer drug distribution method that foreign pharmaceutical companies and large domestic pharmaceutical companies used to suppl
- Policy
- Will Rinvoq be approved for atopic dermatitis?
- by Lee, Tak-Sun Sep 28, 2021 05:54am
- Whether AbbVie Korea’s ‘Rinvoq SR,’ which has been prescribed with reimbursement as an oral rheumatoid arthritis treatment since last year, will add an indication for atopic dermatitis, is gaining attention. The industry believes it is highly possible, as the higher-dose formulation is soon to be approved in Korea, and the drug was app
- Policy
- Pfizer vaccine for 1.67 million doses, about to be discarded
- by Lee, Jeong-Hwan Sep 28, 2021 05:53am
- Among the COVID-19 vaccines supplied in Korea, the vaccine with the most imminent expiration date was the Pfizer vaccine. Pfizer had about 1.67 million in stock and Janssen had about 720,000 in stock for supplies that remained within a month of expiration. Kang Ki-yoon, a member of the People Power Party, made the remarks in a data submitted
- Policy
- 129 drug price reduction starting in October
- by Kim, Jung-Ju Sep 28, 2021 05:53am
- Drugs that sell a lot or have a high price range will be lowered as of the 1st of next month. It will be reduced by up to 10%. It also included seven Choline alfoscerates that negotiated the redemption of drug costs for clinical revaluation. AstraZeneca's Lynparza 50mg, Kadcyla 100mg, and Kadcyla 160mg succeeded in risk-sharing contracts (RSA),
- Policy
- Is the third Avastin biosimilar coming out?
- by Lee, Tak-Sun Sep 27, 2021 05:51am
- Attention is focusing on whether another company will release an Avastin (Bevacizumab) biosimilar approved by Samsung Bioepis and Pfizer. This is because it was found that a new item was approved by the MFDS in August. If the item is approved, a total of four items, including the original Avastin by Roche and three biosimilars, are expect
